Álvarez-Sierra D, Marín-Sánchez A, Ruiz-Blázquez P, de Jesús Gil C, Iglesias-Felip C, González Ó, Casteras A, Costa RF, Nuciforo P, Colobran R, Pujol-Borrell R (2019) Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. J Autoimmun. https://doi.org/10.1016/j.jaut.2019.05.013

Article  PubMed  Google Scholar 

Boussiotis VA (2016) Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med 375(18):1767–1778. https://doi.org/10.1056/NEJMra1514296

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brilli L, Danielli R, Campanile M, Secchi C, Ciuoli C, Calabrò L, Pilli T, Cartocci A, Pacini F, Di Giacomo AM, Castagna MG (2021) Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy. J Endocrinol Invest 44(8):1719–1726. https://doi.org/10.1007/s40618-020-01480-6

Article  CAS  PubMed  Google Scholar 

Byrne EH, Fisher DE (2017) Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer 123(S11):2143–2153. https://doi.org/10.1002/cncr.30444

Article  PubMed  Google Scholar 

Castinetti F, Albarel F, Archambeaud F, Bertherat J, Bouillet B, Buffier P, Briet C, Cariou B, Caron P, Chabre O, Chanson P, Cortet C, Do Cao C, Drui D, Haissaguerre M, Hescot S, Illouz F, Kuhn E, Lahlou N, Merlen E, Raverot V, Smati S, Verges B, Borson-Chazot F (2019) French endocrine society guidance on endocrine side effects of immunotherapy. Endocr Relat Cancer 26(2):G1–G18. https://doi.org/10.1530/ERC-18-0320

Article  CAS  PubMed  Google Scholar 

Chalan P, Di Dalmazi G, Pani F, De Remigis A, Corsello A, Caturegli P (2018) Thyroid dysfunctions secondary to cancer immunotherapy. J Endocrinol Invest 41(6):625–638. https://doi.org/10.1007/s40618-017-0778-8

Article  CAS  PubMed  Google Scholar 

Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L (2019) Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev 40(1):17–65. https://doi.org/10.1210/er.2018-00006

Article  PubMed  Google Scholar 

Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, Gelber RD, Goldhirsch A (2018) Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol 19(6):737–746. https://doi.org/10.1016/S1470-2045(18)30261-4

Article  CAS  PubMed  Google Scholar 

de Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B, Neyns B, Bravenboer B (2016) Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab 101(11):4431–4439. https://doi.org/10.1210/jc.2016-2300

Article  CAS  PubMed  PubMed Central  Google Scholar 

Delivanis DA, Gustafson MP, Bornschlegl S, Merten MM, Kottschade L, Withers S, Dietz AB, Ryder M (2017) Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms. J Clin Endocrinol Metab 102(8):2770–2780. https://doi.org/10.1210/jc.2017-00448

Article  PubMed  PubMed Central  Google Scholar 

Dinesh RK, Hahn BH, Singh RP (2010) PD-1, gender, and autoimmunity. Autoimmun Rev 9(8):583–587. https://doi.org/10.1016/j.autrev.2010.04.003

Article  PubMed  PubMed Central  Google Scholar 

Dougan M, Pietropaolo M (2020) Time to dissect the autoimmune etiology of cancer antibody immunotherapy. J Clin Invest 130(1):51–61. https://doi.org/10.1172/JCI131194

Article  CAS  PubMed  PubMed Central  Google Scholar 

España S, Montes Pérez, de Oca A, Marques-Pamies M, Cucurull M, Domenech M, Velarde JM, Salinas I, Moran T, Etxaniz O (2020) Endocrine adverse events related to immune-oncology agents: retrospective experience of a single institution. Transl Lung Cancer Res. https://doi.org/10.21037/tlcr.2019.12.17

Article  PubMed  PubMed Central  Google Scholar 

Ferrari SM, Fallahi P, Galetta F, Citi E, Benvenga S, Antonelli A (2018) Thyroid disorders induced by checkpoint inhibitors. Rev Endocr Metab Disord 19(4):325–333. https://doi.org/10.1007/s11154-018-9463-2

Article  PubMed  Google Scholar 

Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22(4):886–894. https://doi.org/10.1158/1078-0432.CCR-15-1136

Article  CAS  PubMed  Google Scholar 

Gubbels Bupp MR, Jorgensen TN (2018) Androgen-induced immunosuppression. Front Immunol. https://doi.org/10.3389/fimmu.2018.00794

Article  PubMed  PubMed Central  Google Scholar 

Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [published correction appears in Ann Oncol. 2018 Oct 1;29(Suppl 4):iv264-iv266]. Ann Oncol. 2017;28(suppl_4):iv119-iv142. doi:https://doi.org/10.1093/annonc/mdx225

Hargadon KM, Johnson CE, Williams CJ (2018) Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol 62:29–39. https://doi.org/10.1016/j.intimp.2018.06.001

Article  CAS  PubMed  Google Scholar 

Kazandjian D, Gong Y, Keegan P, Pazdur R, Blumenthal GM (2019) Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small cell lung cancer. JAMA Oncol 5(10):1481–1485. https://doi.org/10.1001/jamaoncol.2019.1747

Article  PubMed  PubMed Central  Google Scholar 

Khan S, Gerber DE (2020) Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review. Semin Cancer Biol 64:93–101. https://doi.org/10.1016/j.semcancer.2019.06.012

Article  CAS  PubMed  Google Scholar 

Kimbara S, Fujiwara Y, Iwama S, Ohashi K, Kuchiba A, Arima H, Yamazaki N, Kitano S, Yamamoto N, Ohe Y (2018) Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. Cancer Sci 109(11):3583–3590. https://doi.org/10.1111/cas.13800

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kotwal A, Gustafson MP, Bornschlegl S, Kottschade L, Delivanis DA, Dietz AB, Gandhi M, Ryder M (2020) Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal t lymphocyte subpopulations. Thyroid 30(10):1440–1450. https://doi.org/10.1089/thy.2020.0075

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lima Ferreira J, Costa C, Marques B, Castro S, Victor M, Oliveira J, Santos AP, Sampaio IL, Duarte H, Marques AP, Torres I (2021) Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors. Cancer Immunol Immunother 70(2):299–309. https://doi.org/10.1007/s00262-020-02664-y

Article  CAS  PubMed  Google Scholar 

Liu H, Yang XL, Yang XY, Dong ZR, Chen ZQ, Hong JG, Li T (2021) The prediction potential of the pretreatment lung immune prognostic index for the therapeutic outcomes of immune checkpoint inhibitors in patients with solid cancer: a systematic review and meta-analysis. Front Oncol. https://doi.org/10.3389/fonc.2021.691002

Article  PubMed  PubMed Central  Google Scholar 

Luo J, Martucci VL, Quandt Z, Groha S, Murray MH, Lovly CM, Rizvi H, Egger JV, Plodkowski AJ, Abu-Akeel M, Schulze I, Merghoub T, Cardenas E, Huntsman S, Li M, Hu D, Gubens MA, Gusev A, Aldrich MC, Hellmann MD, Ziv E (2021) Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with pd-1 blockade in non-small cell lung cancer. Clin Cancer Res 27(18):5131–5140. https://doi.org/10.1158/1078-0432.CCR-21-0921

Article  CAS  PubMed  PubMed Central  Google Scholar 

Meyers DE, Stukalin I, Vallerand IA, Lewinson RT, Suo A, Dean M, North S, Pabani A, Cheng T, Heng DYC, Bebb DG, Morris DG (2019) The lung immune prognostic index discriminates survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors. Cancers (Basel). https://doi.org/10.3390/cancers11111713

Article  PubMed  Google Scholar 

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B (2018) Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol 4(3):351–357. https://doi.org/10.1001/jamaoncol.2017.4771

Article  PubMed  PubMed Central  Google Scholar 

Moulton VR (2018) Sex hormones in acquired immunity and autoimmune disease. Front Immunol. https://doi.org/10.3389/fimmu.2018.02279

Article  PubMed  PubMed Central  Google Scholar 

Muir CA, Clifton-Bligh RJ, Long GV, Scolyer RA, Lo SN, Carlino MS, Tsang VHM, Menzies AM (2021) Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J Clin Endocrinol Metab 106(9):e3704–e3713. https://doi.org/10.1210/clinem/dgab263

Article  PubMed  Google Scholar 

Okada N, Iwama S, Okuji T, Kobayashi T, Yasuda Y, Wada E, Onoue T, Goto M, Sugiyama M, Tsunekawa T, Takagi H, Hagiwara D, Ito Y, Suga H, Banno R, Hase T, Morise M, Kanda M, Yokota K, Hashimoto N, Ando M, Fujimoto Y, Nagino M, Kodera Y, Fujishiro M, Hibi H, Sone M, Kiyoi H, Gotoh M, Ando Y, Akiyama M, Hasegawa Y, Arima H (2020) Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study. Br J Cancer 122(6):771–777. https://doi.org/10.1038/s41416-020-0736-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D, Rodriguez C, Cambridge L, Rizvi H, Wolchok JD, Merghoub T, Rudin CM, Fish S, Hellmann MD (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28(3):583–589. https://doi.org/10.1093/annonc/mdw640

Article  CAS  PubMed